
|Articles|November 16, 2012
Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events
Adding aliskiren to standard therapy with renin-angiotensin system blockade could be harmful and did not lower the risk of cardiovascular and renal adverse events when used in patients with type 2 diabetes at risk for these events, according to an online study in the New England Journal of Medicine.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Explaining COVID-19 Vaccine Side Effects to Anxious Patients
4
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
5







































